Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
- 5.9k Downloads
Major progress for the management of invasive aspergillosis has come from the introduction of new antifungals since the late 1990s. Although mortality of invasive aspergillosis remains as high as 30-50%. Backbone of management are prophylaxis, early diagnosis and early initiation of antifungals for reduction of invasive aspergillosis related mortality. Randomized trials have been undertaken for the prophylaxis as well as treatment of invasive aspergillosis in the last two decades. Posaconazole is recommended for prophylaxis against aspergillosis in patients treated for acute myelogenous leukemia, myelodysplastic syndrome or patients with graft versus host disease after allogeneic transplantation. Efficacy has been shown for first-line therapy of invasive aspergillosis with voriconazole and liposomal amphotericin B. Gastrointestinal resorption for the azoles posaconazole, voriconazole and itraconazole differ considerably. While oral voriconazole resportion is reduced when taken with food, posaconazole has to be taken with fatty food for optimal intestinal resorption. Beside all advances in the management of invasive aspergillosis important questions remain unresolved. This article reviews the current state of prophylaxis and treatment of invasive aspergillosis and points out clinicians unmet needs.
KeywordsFluconazole Itraconazole Voriconazole Aspergillosis Invasive Aspergillosis
Risk Factors for Invasive Aspergillus Infections
severe and long lasting neutropenia
bone marrow transplantation
acute and chronic graft-versus-host disease
continuous use of steroids
uncontrolled construction work
sustainded immune suppression
Important causative Aspergillus species with Opportunistic Infections in Human
Polyenes were introduced for antifungal treatment in the late 1950s. Amphotericin B desoxycholate (AmB) is proven to be effective but toxic. AmB has a lot of severe adverse events including nephrotoxicity and infusion related side effects. Although prolongation of infusion time from two to four and up to 24 h has been shown to be less toxic , recent guidelines have dumped amphotericin B desoxycholate for prophylaxis and empirical treatment [9, 10]. Three lipid based amphotericin B formulations have been introduced since the 1990s. Out of these, liposomal amphotericin B (LAmB) has proved to overcome a substantial number of adverse events. LAmB is significantly less nephro-toxic and associated with fewer infusion-related side effects. Randomized trials with LAmB have shown efficacy comparable with amphotericin B desoxycholate for empirical antifungal therapy in patients with febrile neutropenia refractory to broad-spectrum antibiotics [11, 12]. New azoles were introduced with susceptibility against Aspergillus species. These second generation azoles have been studied for prophylaxis and treatment since the late 1990s. Voriconazole and posaconazole proved efficacy. Voriconazole is approved for 1st-line treatment of invasive aspergillosis, while posaconazole is approved for prophylaxis of invasive fungal infections and 2nd-line treatment of invasive aspergillosis.
Echinocandins are a new class of antifungals. Echinocandins inhibit the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall. They exhibit potent in vitro and in vivo antifungal activity against Candida and Aspergillus species. Caspofungin, Micafungin and Anidulafungin are approved for antifungal treatment in the EU. There was no substantial difference in efficacy with liposomal amphotericin B in comparison with caspofungin in a randomized trial for treatment of febrile neutropenia . Nephrotoxicity and adverse events were observed less frequent in patients treated with caspofungin. With the introduction of these new and safer antifungals with a proven efficacy against aspergillosis prophylaxis has become a major issue and reasonable field for clinical investigation.
Current options for prophylaxis of invasive aspergillosis
Fluconazole was introduced for prophylaxis of invasive fungal infections in the early 1990s. Two randomized, placebo-controlled trials showed that fluconazole (400 mg/d) administered prophylactically decreased the incidence of candidiasis in blood and marrow transplant (BMT) recipients [14, 15]. In allogeneic bone marrow transplant (BMT) recipients the use of fluconazole (400 mg/d) administered over a period of 75 days following BMT resulted in a decreased rate of gut graft versus host disease (GvHD) and a persistent protection against disseminated Candida infections and candidiasis-related death in addition to an overall survival benefit . Fluconazole has major drawbacks due to a growing emergence of non-albicans species with reduced fluconazole susceptibility and what is more important a lack of efficacy against moulds as Aspergillus species. Targeted prophylaxis against aspergillosis is therefore a need and can not be covered by fluconazole.
Two randomized controlled trials evaluated the prophylactic use of posaconazole in acute leukemia and in the allogeneic hematopoietic stem cell transplant (HSCT) setting [17, 18]. A total of 304 patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) that had a chemotherapy-associated neutropenia were treated in a randomized, multi-center study comparing posaconazole (3 × 200 mg/d) with fluconazole (1 × 400 mg) or itraconazole (2 × 200 mg) as antifungal prophylaxis. Primary endpoint was the incidence of proven or probable invasive fungal infections during treatment. Proven or probable invasive fungal infections were reported in 7 patients (2%) in the posaconazole group and 25 patients (8%) in the fluconazole or itraconazole group (P < 0.001). Significantly fewer patients in the posaconazole group had invasive aspergillosis (2[1%] vs. 20 [7%], P < 0.001). In a second trial, oral posaconazole was compared with fluconazole p.o. for prophylaxis in patients with graft-versus-host disease (GvHD). The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study. In the posaconazole group were fewer breakthrough invasive fungal infections (2.4% vs. 7.6%, P = 0.004), particularly invasive aspergillosis (1.0% vs. 5.9%, P = 0.001). Although overall mortality was similar in the two groups, the number of deaths from invasive fungal infections was reported lower under posaconazole (1%, vs. 4%; P = 0.046). Both posaconazole trials proved to be effective in the reduction of invasive fungal infections in particular against aspergillosis.
Three glucan synthesis inhibitors were studied for prophylaxis and/or for treatment of invasive fungal infections. Out of these three echinocandins, micafungin has been studied for prophylaxis in the transplant setting. In a randomized, double-blind, phase III trial, 882 adult and pediatric patients received 50 mg of micafungin i.v. (1 mg/kg in pts < 50 kg) or 400 mg fluconazole (8 mg/kg in pts < 50 kg) administered once daily. The overall efficacy defined as absence of proven, probable, or suspected systemic fungal infection through the end of prophylaxis with micafungin was superior to fluconazole as during the neutropenic period after HSCT (P = .03) .
Liposomal amphotericin B is a lipid formulation of amphotericin B with hydrogenated soy phosphatidyl-choline, distearoylphophatidylglycerol, and cholesterol. The lipid formulation was developed to obtain a lower toxicity. LAmB was studied in a randomized, unblinded trial comparing intravenous LAmB prophylaxis with no systemic antifungal prophylaxis during neutropenia (50 mg of LAmB as a 1-h infusion every other day) . Invasive aspergillosis occurred less frequently in patients receiving LAmB-prophylaxis (P = 0.0057), whereas the reduction of invasive candidiasis did not reach statistical significance (P = 0.0655). Liposomal amphotericin has been compared to placebo by using an inhalative setting (twice a week) in 271 patients with 407 neutropenic episodes (≥10 days). The primary end point was occurrence of invasive pulmonary aspergillosis (IPA). Six patients with LAmB prophylaxis versus 18 placebo patients of developed IPA (P = .005) .
In recent years several attempts have been undertaken to prove the efficacy of voriconazole for prophylaxis of invasive fungal infections in hematology malignancies. Studies were done in the transplant and non transplant setting . In a comparative study with allogeneic HSCT-recipients the rates of invasive fungal infections at 6 months were 6.6% in the voriconazole and 10.6% in the fluconazole arm. There was a trend towards fewer Aspergillus infections in the voriconazole arm without being superior to fluconazole (p = 0.11). In addition overall survival at day +180 was not different between both arms (81% vs 80%). Trials so far had not the design to show differences between voriconazole and fluconazole according to anti-fungal prophylaxis of invasive aspergillosis, because they didn't compare the same endpoint of treatment. The conceivable value of voriconazole for break-through fungal infection after posaconazole prophylaxis is not yet studied in prospective controlled trials.
Itraconazole has been available since the early 1990s. It was studied extensively in the 1990s for prophylaxis of invasive fungal infections. It has been available as oral capsules (since 1992), oral solution in cyclodextrin (since 1997) and intravenous formulation(since 1999). Itraconazole is highly lipophilic. Intestinal absorption of itraconazole oral capsules is variable and unpredictable. Oral solution of itraconazole has a better bioavailability compared to capsules. Most single trials did not prove efficacy against invasive aspergillosis infections. Adverse events, intestinal absorption as well as interactions are a major drawback of oral itraconazole when used for prophylaxis. A meta-analysis showed superiority of itraconazole when compared with fluconazole in hematological malignancies. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution and not itraconazole capsules. The overall mortality was not reduced .
Evidence based recommendations for aspergillus prophylaxis
Infectious disease guidelines recommend prophylaxis against aspergillosis on data of randomized controlled trials. Posaconazole 600 mg/d is strongly recommended in patients with acute myelogenous leukemia/myelodysplastic syndromes or undergoing allogeneic stem cell recipients with graft versus host disease for the prevention of invasive fungal infections and attributable mortality of invasive aspergillosis (Level A I). Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II). There is moderate evidence of voriconazole for prophylaxis of invasive fungal infections measured and compared eighty days after end of prophylaxis .
Physicians are now headed with the management of suspected fungal infections in febrile neutropenic patients undergoing posaconazole prophylaxis. Posaconazole prophylaxis failure was rare in the trials that led to the approval of posaconazole. Fever refractory to antibiotics despite posaconazole prophylaxis remains a common clinical scenario during the course of leukemia treatment however. Wait and see or change of antifungal treatment is the question . IFI under posaconazole prophylaxis were diagnosed in 2% and 5% of patients with AML and allogeneic HSCT-recipients with GvHD, respectively. A posaconazole trough threshold of 0.5 μg/ml has been proposed for optimized antifungal prevention. Statistically different posaconazole plasma concentrations have been observed under various conditions. There is a matter of debate what is clinically relevant . Thus, drug monitoring of triazole serum concentrations may become important to minimize toxicity and ensure efficacy [28, 29, 30]. Kohl et al elucidated factors influencing the pharmacokinetics of posaconazole administered in HSCT-recipients for prophylaxis. Among the covariates tested, significant effects were found for age (decrease in the volume of distribution of 123 liters per year of age) and the presence of diarrhea (59% loss of bioavailability). A basis for prediction of the mean posaconazole concentrations in allogeneic SCT recipients with hematological malignancies is provided for a given dose. Corresponding adjustments of the starting dose according to the presence of diarrhea, and according to age appear to be justified .
A French trial retrospectively analyzed low posaconazole plasma concentrations (PPC) defined as a concentration lower than 500 ng/ml. Fifty-four patients were included: 36 receiving prophylactic (200 mg three times a day) and 18 receiving curative (400 mg twice a day) doses of posaconazole. The prevalence of low PPCs was 44% (16/36) in the prophylaxis group and 22% (4/18) in the curative-treatment group. In the prophylaxis group, low PPCs tended to be more frequent in cases of digestive disease (62.5% versus 30%; P = 0.051) and were significantly more frequent among patients with diarrhea (71.4% versus 27%; P = 0.009) or mucositis (100% versus 33%; P = 0.004). In the curative-treatment group, low PPCs were significantly more frequent in cases of diarrhea (75% versus 7%; P = 0.018) . Taken together the results of these two trials suggest that therapeutic drug monitoring of posaconazole is mandatory in immunosuppressed patients, at least in those with gastrointestinal disorders and the administration of proton pump inhibitors. Patients with fever during posaconazole prophylaxis might be switched to an intravenous broad spectrum antimycotic, at least in cases of mucositis and diarrhea. Breakthrough fungal infections caused by Zygomycosis should be taken into account, in particular for those patients receiving voriconazole for prophylaxis . Case reports with proven pneumonia due to Rhizopus after long standing posaconazole prophylaxis have also been published recently . Fasting serum levels were in a range of 691-904 ng/mL in one of the cases . The presented cases had severe graft-versus-host disease after allogeneic stem cell transplantation associated with an impaired intestinal absorption of posaconazole.
Management of invasive aspergillosis
Patients at highest risk are those with hematological malignancies and severe neutropenia. Emerging data have shown that solid organ transplant recipients, chronic obstructive pulmonary disease and patients in the intensive care unit receiving steroids might have a risk for invasive aspergillosis too. Non-neutropenic, non-hematological patients now account for up to 40% of all those with invasive aspergillosis. For these latter patients there is less knowledge of the management. The approaches that have been proven to be effective in the neutropenic host may also benefit in these patient groups. Early and effective treatment with maximum tolerable dosages of antifungal agents is the backbone of treatment.
For decades Amphotericin B desoxycholate has been the only option for invasive aspergillosis until the early 1990s. The introduction of voriconazole has been a major progress. Voriconazole has a broad antifungal efficacy, including Aspergillus species. Patients with definitive or probable invasive aspergillosis were studied in an open randomized trial that compared voriconazole (2 × 6 mg/kg on day 1 and 2 × 4 mg/kg/d for seven days i.v. followed by p.o treatment) with amphotericin B desoxycholate (1-1,5 mg/kg/d). At week 12 response was observed in 52.8% in the voriconazole and 31.6% in the amphotericin B group. Patients in the voriconazole arm had a significant improved survival at week 12 (70.8% vs 57.9%). Toxicity was lower for patients receiving voriconazole beside visual disturbances . Since that trial voriconazole has been adopted gold standard for the treatment of invasive Aspergillosis. One might argue that amphotericin B desoxycholat may not have been the optimal competitor, since amphotericin B could be administered a median of 10 days only . Amphotericin B desoxycholate was the only approved drug for first-line treatment at that time the trial was designed, however. Treatment with voriconazole proved to be effective even in patients with disseminated aspergillosis infections. Moreover, voriconazole penetrates the central nervous system (CNS). Patients with invasive aspergillosis of the CNS are known to have a very bad prognosis with a mortality of 90%. Voriconazole showed superior efficacy and survival with a response in 35% of patients (survival 31%) . Although voriconazole is well absorbed from the gut there has been reported a large inter-individual variability in voriconazole through blood levels. Voriconazole blood levels of > 1 mg/L are considered a minimum inhibitory concentration. Lack of response has been observed in patients with voriconazole levels < 1 mg/L [39, 40]. Efficacy against invasive fungal infections was documented after increasing the voriconazole dosage. Therefore, therapeutic drug monitoring of voriconazole is recommended in particular for those patients not responding under oral voriconazole treatment. Higher voriconazole levels ( > 5.5 mg/L) in contrast are associated with increased adverse events, in particular encephalopathy due to voriconazole. Co-medication with omeprazole has been observed with voriconazole accumulation. In these cases discontinuation of therapy resulted in complete neurological recovery.
Liposomal amphotericin B
Treatment of invasive aspergillosis needs maximum tolerable dosages of antifungal drugs. Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day. Induction treatment of proven or probable invasive aspergillosis with high dose (10 mg/kg) LAmB was compared in a double-blind trial. 201 Patients with mold infection were randomized to receive LAmB at either 3 or 10 mg/kg per day for 14 days, followed by 3 mg/kg per day. The primary end point was complete or partial response. A favorable response was achieved in 50% and 46% of patients in the 3- and 10-mg/kg groups, respectively (P > .05). Survival rates at 12 weeks were 72% and 59% (P > .05). Significantly higher rates of nephrotoxicity and hypokalemia were seen in the high-dose group. Liposomal Amphotericin B has been approved for first-line treatment of invasive fungal infection . The AmBiLoad trial was not a comparison to voriconazole what has to be taken into account. Although response and survival rates were in the range of voriconazole for first-line therapy of invasive aspergillosis. A head to head comparison of both drugs for efficacy against invasive aspergillosis is lacking.
Echinocandins for the management of invasive aspergillosis
First-line Treatment of Invasive Aspergillosis: Prospective Controlled Trials
Survival week 12
AmB Desoxycholate 1-1.5 mg/kg
Vori 2 × 6 mg/kg d1 and 2 × 4 mg/kg d2+ i.v.*
LAmB 3mg/kg (d1-14)
} op3mg/kg d 15 +
LAmB 10 mg/kg (d1-14)
Herbrecht 2010 BMT **
Caspofungin 70mg d1/50 mg d2+
Viscoli 2009JAC #
Caspofungin 70mg d1/50 mg d 2+
Micafungin and anidulafungin are also approved for the treatment of invasive Candidiasis with fewer data in hematological patients [46, 47, 48]. However, both drugs have not been proven to be effective for first-line treatment for invasive aspergillosis whereas some data are available on micafungin for refractory aspergillosis .
Posaconazole for treatment of invasive aspergillosis
Currently there are no data for the first-line treatment from randomized trials. The posaconazole salvage study was conducted in patients with refractory or intolerant invasive mycoses . These patients were not randomized in a controlled clinical trial but were included as a prespecified control group in the original study plan using retrospective data. A data review committee of 15 experts in antifungal therapy and 2 radiologists assessed posaconazole-treated subjects and control subjects in a parallel, blinded manner using predefined methods to assess evaluability and outcome. Cases of aspergillosis deemed evaluable by a blinded data review committee included 107 posaconazole recipients and 86 control subjects (modified intent-to-treat population). The overall success rate was 42% for posaconazole recipients and 26% for control subjects (P = .006). The 2nd-line data of posaconazole treatment of IA showed efficacy in patients failing first-line treatment. These data do not allow to estimate efficacy in the first-line treatment of IA with posaconazole.
Itraconazole for invasive aspergillosis
Intravenous itraconazole circumvents problems with intestinal absorption. Intravenous followed by oral itraconazole has been reported for the treatment of invasive aspergillosis in a non-randomized trial . An open, international, multicenter trial evaluated the efficacy and safety of i.v. followed by oral itraconazole capsules in patients with invasive pulmonary aspergillosis. Patients received 200 mg itraconazole by an iv infusion over 60-90 min every 12 h for the first 2 days. For the following 12 days, 200 mg itraconazole was administered by iv infusion once daily. Oral itraconazole capsules (200-mg) were then administered twice daily from weeks 3-14. Median iv itraconazole was 14 days with mean trough concentrations of itraconazole after 2 and 14 days 670 and 850 ng/mL, respectively. A complete or partial response was seen at the last on-treatment assessment in 15 (48%) of 31 patients, with 6 (19%) showing stable disease.
Management of invasive aspergillosis with GM-Monitoring
Since the widespread use of posaconazole for prophylaxis in high risk hematological malignancies management of suspected invasive aspergillosis has raised new questions in particular, the definition of break-through aspergillus infection. Is this refractory fever under posaconazole prophylaxis, or fever under posaconazole and new lung infiltrates?
Galactomannan (GM) screening has been introduced in recent years . We have learned to use this diagnostic tool for early detection of invasive aspergillosis . These data were obtained prior to the introduction of posaconazole for prophylaxis. The role of quantitative GM-serum levels in patients under prophylaxis with posaconazole remains a matter of debate. Different clinical scenarios may be encountered: patients who develop new fever without any new lung infiltrates, patients with newly diagnosed febrile episodes and new lung infiltrates in the absence of a positive GM-assay, and patients with fever plus/minus new lung infiltrates and a positive serum GM. Monitoring aspergillosis response to therapy by conventional clinical, radiological, and microbiological methods remains challenging, because it includes subjective and nonspecific signs, symptoms of infection, and interpretation of radiological findings that are neither standardized nor validated. A decrease of GM in patients with proven aspergillosis might be helpful for the interpretation of radiological findings during the course of the disease. A normalization of GM is not enough to terminate antifungal treatment.
If failure of posaconazole prophylaxis is suspected, a thorough clinical investigation is necessary. This includes control of compliance with oral posaconazole ingestion, timepoint of administration (Posaconazole administered at dosages of 600-800 mg/day in divided doses with food) and signs and symptoms of diarrhea or gastrointestinal GvHD. Determining posaconazole serum/plasma concentration seems to be helpful but the assessment of serum levels is not a routine in daily practice. If fever is the only symptom in a patient with adequate posaconazole serum levels, a wait and see policy is justified.
By contrast, posaconazole prophylaxis may be terminated in patients with a worsening clinical condition. In particular breakthrough infections related to Zygomycosis have to be ruled out or should be taken into account. Awareness of the local epidemiology may be important . For patients developing new lung infiltrates or symptoms of acute rhinosinusitis while being on posaconazole for IFI prophylaxis a switch to other licensed antifungals should be considered. There are no data from clinical trials supporting the use of voriconazole or an echinocandin in patients who develop fever under posaconazole prophylaxis. Of note, voriconazole and the echinocandins have no clinical efficacy against Zygomycosis. A combination therapy would be of particular interest, e.g. posaconazole plus liposomal amphotericin B or an echinocandin. Data from controlled clinical trials supporting this concept may be available by the end of 2011. At present a change to lipid-based amphotericin B seems to be reasonable for patients with posaconazole prophylaxis with a worsening clinical condition that is suspected to be related to an invasive aspergillosis. Amphotericin B has a broader spectrum of activity compared to azoles and echinocandins. Furthermore, amphotericin B covers most Candida species and has activity against Trichosporum, Blastomyces, Cryptococci as well as Zygomycosis.
Combination of antifungal agents against invasive aspergillosis
Combined, simultaneous or sequential antifungal therapy are often been considered an appropriate option for salvage treatment of invasive aspergillosis. Preliminary data suggest that the combination of azoles or LAmB and echinocandins may increase activity against refractory IA [55, 56]. Anidulafungin belongs to the echinocandin family. A randomized double-blind placebo controlled Phase III trial compares efficacy of voriconazole plus anidulafungin or placebo. This trial has stopped enrolment. Data are suspected in late 2011.
It should be emphasized that antifungal prophylaxis will remain a standard approach in patients at high risk for invasive fungal infections while meticulous clinical judgement and treatment of febrile neutropenic episodes remain necessary. New aszoles, lipid based amphotericin and the echinocandins have improved the management of invasive aspergillosis. Patients with invasive aspergillosis must closely be monitored. A switch of the antifungal regimen may help to achieve a better outcome of patients worsening under posaconazole prophylaxis. The question which antifungal should be used has to be answered by well-designed prospective clinical trials.
- 5.De Pauw B, Walsh TJ, Donnelly JP, et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008,46(12):1813–21. 10.1086/588660PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, et al.: Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009,88(2):97–110. 10.1007/s00277-008-0622-5CrossRefGoogle Scholar
- 11.Walsh TJ, Finberg RW, Arndt C, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999,340(10):764–71. 10.1056/NEJM199903113401004PubMedCrossRefGoogle Scholar
- 19.van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004,39(10):1407–16. 10.1086/422312PubMedCrossRefGoogle Scholar
- 20.Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW: Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006,17(8):1306–12. 10.1093/annonc/mdl128PubMedCrossRefGoogle Scholar
- 21.Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008,46(9):1401–8. 10.1086/586739PubMedCrossRefGoogle Scholar
- 23.Wingard JR, Carter SL, Walsh TJ, et al.: Blood an Marrow Transplant Clinical Trials Network. Randomized, doubleblind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010,116(24):5111–8. 10.1182/blood-2010-02-268151PubMedCentralPubMedCrossRefGoogle Scholar
- 25.Cornely OA, Böhme A, Buchheidt D, et al.: Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009,94(1):113–22. 10.3324/haematol.11665PubMedCentralPubMedCrossRefGoogle Scholar
- 28.Ullmann AJ, Cornely OA, Burchardt A, et al.: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006,50(2):658–66. 10.1128/AAC.50.2.658-666.2006PubMedCentralPubMedCrossRefGoogle Scholar
- 29.Lipp HP: Posaconazole:clinical pharmacokinetics and drug interactions. Mycoses 2011, (Suppl 1):32–8.Google Scholar
- 30.Shields RK, Clancy CJ, Vadnerkar A, et al.: Posaconazole serum concentrations among cardiothoracic transplant reciepients: Factors influencing levels and correlation with clinical response. Antimicrob Agents Chemother 2010, in press. 2010Google Scholar
- 33.Trifilio SM, Bennett Cl, Yarnold PR, et al.: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007,39(7):425–9. 10.1038/sj.bmt.1705614PubMedCrossRefGoogle Scholar
- 55.Kontoyiannis DP, Ratanatharathorn V, Young JA, et al.: Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009,11(1):89–93. 10.1111/j.1399-3062.2008.00349.xPubMedCrossRefGoogle Scholar